CRBU Stock — Caribou Biosciences Inc.: Cash, EV, Pipeline

Share price

$1.30

Market cap

$139.4M

Cash

$112.3M

Enterprise value

$27.1M

Balance sheet

Cash	$112.3M
Debt	$0.0M
Net cash	$112.3M
Enterprise value	$27.1M
Basic shares	106.0M shares
Fully diluted shares	135.4M shares
Fully diluted market cap	$176.1M
Cash per share	$1.06

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CRBU daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	CB-011	Phase 1	Relapsed/Refractory Multiple Myeloma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

vispacabtagene regedleucel (vispa-cel)

Phase 1 · Active Modality: allogeneic CAR-T (chRDNA genome-edited, PDCD1 knockout)

Aliases vispa-cel, formerly CB-010

Target CD19

Indications

Relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) (Phase 1)
Second-line large B-cell lymphoma (2L LBCL), transplant-ineligible (Phase 3)

Status note Lead program; ANTLER Phase 1 in r/r B-NHL ongoing. FDA alignment on pivotal Phase 3 ANTLER-3 design reached May 7, 2026 (~250 CD19-naive 2L LBCL patients, vispa-cel vs investigator's choice). RMAT (r/r LBCL), Fast Track (r/r B-NHL), Orphan (follicular lymphoma). No dated start/readout stated in this filing. Company discontinued preclinical research and two unnamed clinical programs (April 2025) with a ~32% workforce cut.

CB-011

Phase 1 · Active Modality: allogeneic CAR-T (chRDNA genome-edited, immune cloaking via B2M removal + B2M-HLA-E insertion)

Target BCMA

Indications

Relapsed/refractory multiple myeloma (r/r MM) (Phase 1)

Status note CaMMouflage Phase 1 in 4L+ r/r MM; dose expansion (RDE 450x10^6 cells) initiated late 2025 and ongoing, enrolling BCMA-naive and BCMA-exposed cohorts. RMAT, Fast Track and Orphan Drug designations for r/r MM.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CB-011
Lead indication	Relapsed/Refractory Multiple Myeloma
Lead phase	Phase 1
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05722418	Phase 1	Recruiting	Sponsor	CRBU	—	Relapsed/Refractory Multiple Myeloma	—
NCT05332054	Not disclosed	Enrolling by invitation	Sponsor	CRBU	—	Lymphoma, Non-Hodgkin; Relapsed Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Caribou Biosciences, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

CRBU — Caribou Biosciences Inc.